Catalyst
Slingshot members are tracking this event:
VX-661 and ivacaftor did not result in a pre-specified improvement in lung function in people with mutations that result in minimal CFTR function; Vertex plans to close this study based on the recommendation of the DSMB
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 15, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Vx-661, Cftr Function, Dsmb, Termination
